FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801785887> ?p ?o ?g. }

• W2801785887 endingPage "2784" @default.
• W2801785887 startingPage "2770" @default.
• W2801785887 abstract "Neovascular age-related macular degeneration (wet AMD) results from the pathological angiogenesis of choroidal capillaries, which leak fluid within or below the macular region of the retina. The current standard of care for treating wet AMD utilizes intravitreal injections of anti-VEGF antibodies or antibody fragments to suppress ocular vascular endothelial growth factor (VEGF) levels. While VEGF suppression has been demonstrated in wet AMD patients by serial measurements of free-VEGF concentrations in aqueous humor samples, it is presumed that anti-VEGF molecules also permeate across the inner limiting membrane (ILM) of the retina as well as the retinal pigmented epithelium (RPE) and suppress VEGF levels in the retina and/or choroidal regions. The latter effects are inferred from serial optical coherence tomography (OCT) measurements of fluid in the retinal and sub-retinal spaces. In order to gain theoretical insights to the dynamics of retinal levels of free-VEGF following intravitreal injection of anti-VEGF molecules, we have extended our previous two-compartment pharmacokinetic/pharmacodynamic (PK/PD) model of ranibizumab–VEGF suppression in vitreous and aqueous humors to a three-compartment model that includes the retinal compartment. In the new model, reference values for the macromolecular permeability coefficients between retina and vitreous (pILM) and between retina and choroid (pRPE) were estimated from PK data obtained in rabbit. With these values, the three-compartment model was used to re-analyze the aqueous humor levels of free-VEGF obtained in wet AMD patients treated with ranibizumab and to compare them to the simulated retinal levels of free-VEGF, including the observed variability in PK and PD. We have also used the model to explore the impact of varying pILM and pRPE to assess the case in which an anti-VEGF molecule is impermeable to the ILM and to assess the potential effects of AMD pathology on the RPE barrier. Our simulations show that, for the reference values of pILM and pRPE, the simulated duration of VEGF suppression in the retina is approximately 50% shorter than the observed duration of VEGF suppression in the aqueous humor, a finding that may explain the short duration of suppressed disease activity in the “high anti-VEGF demand” patients reported by Fauser and Muether (Br. J. Ophthalmol. 2016, 100, 1494–1498). At 10-fold lower values of pRPE, the durations of VEGF suppression in the retina and aqueous humor are comparable. Lastly we have used the model to explore the impact of dose and binding parameters on the duration and depth of VEGF suppression in the aqueous and retinal compartments. Our simulations with the three-compartment PK/PD model provide new insights into inter-patient variability in response to anti-VEGF therapy and offer a mechanistic framework for developing treatment regimens and molecules that may prolong the duration of retinal VEGF suppression." @default.
• W2801785887 created "2018-05-17" @default.
• W2801785887 creator A5020813281 @default.
• W2801785887 creator A5025791169 @default.
• W2801785887 creator A5039218029 @default.
• W2801785887 creator A5053331445 @default.
• W2801785887 creator A5087448925 @default.
• W2801785887 creator A5089053900 @default.
• W2801785887 date "2018-05-07" @default.
• W2801785887 modified "2023-10-12" @default.
• W2801785887 title "Theoretical Insights into the Retinal Dynamics of Vascular Endothelial Growth Factor in Patients Treated with Ranibizumab, Based on an Ocular Pharmacokinetic/Pharmacodynamic Model" @default.
• W2801785887 cites W1929050476 @default.
• W2801785887 cites W1968194636 @default.
• W2801785887 cites W1979137922 @default.
• W2801785887 cites W1985695422 @default.
• W2801785887 cites W1986457383 @default.
• W2801785887 cites W1996171994 @default.
• W2801785887 cites W1996375155 @default.
• W2801785887 cites W2009964074 @default.
• W2801785887 cites W2017136158 @default.
• W2801785887 cites W2023453327 @default.
• W2801785887 cites W2032621293 @default.
• W2801785887 cites W2039936409 @default.
• W2801785887 cites W2075652170 @default.
• W2801785887 cites W2086256951 @default.
• W2801785887 cites W2091989599 @default.
• W2801785887 cites W2093044616 @default.
• W2801785887 cites W2098409014 @default.
• W2801785887 cites W2098913603 @default.
• W2801785887 cites W2100591986 @default.
• W2801785887 cites W2107476817 @default.
• W2801785887 cites W2145027167 @default.
• W2801785887 cites W2154770697 @default.
• W2801785887 cites W2160226180 @default.
• W2801785887 cites W2166156136 @default.
• W2801785887 cites W2235873751 @default.
• W2801785887 cites W2322644144 @default.
• W2801785887 cites W2337336780 @default.
• W2801785887 cites W2415022155 @default.
• W2801785887 cites W2701452818 @default.
• W2801785887 cites W4244352700 @default.
• W2801785887 doi "https://doi.org/10.1021/acs.molpharmaceut.8b00280" @default.
• W2801785887 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29734810" @default.
• W2801785887 hasPublicationYear "2018" @default.
• W2801785887 type Work @default.
• W2801785887 sameAs 2801785887 @default.
• W2801785887 citedByCount "31" @default.
• W2801785887 countsByYear W28017858872018 @default.
• W2801785887 countsByYear W28017858872019 @default.
• W2801785887 countsByYear W28017858872020 @default.
• W2801785887 countsByYear W28017858872021 @default.
• W2801785887 countsByYear W28017858872022 @default.
• W2801785887 countsByYear W28017858872023 @default.
• W2801785887 crossrefType "journal-article" @default.
• W2801785887 hasAuthorship W2801785887A5020813281 @default.
• W2801785887 hasAuthorship W2801785887A5025791169 @default.
• W2801785887 hasAuthorship W2801785887A5039218029 @default.
• W2801785887 hasAuthorship W2801785887A5053331445 @default.
• W2801785887 hasAuthorship W2801785887A5087448925 @default.
• W2801785887 hasAuthorship W2801785887A5089053900 @default.
• W2801785887 hasConcept C112705442 @default.
• W2801785887 hasConcept C118487528 @default.
• W2801785887 hasConcept C126322002 @default.
• W2801785887 hasConcept C142724271 @default.
• W2801785887 hasConcept C167734588 @default.
• W2801785887 hasConcept C169760540 @default.
• W2801785887 hasConcept C185592680 @default.
• W2801785887 hasConcept C2776403814 @default.
• W2801785887 hasConcept C2776694085 @default.
• W2801785887 hasConcept C2776694393 @default.
• W2801785887 hasConcept C2777025900 @default.
• W2801785887 hasConcept C2777093970 @default.
• W2801785887 hasConcept C2777802072 @default.
• W2801785887 hasConcept C2778024200 @default.
• W2801785887 hasConcept C2778561011 @default.
• W2801785887 hasConcept C2779742858 @default.
• W2801785887 hasConcept C2780827179 @default.
• W2801785887 hasConcept C2781100027 @default.
• W2801785887 hasConcept C71924100 @default.
• W2801785887 hasConcept C86803240 @default.
• W2801785887 hasConcept C98274493 @default.
• W2801785887 hasConceptScore W2801785887C112705442 @default.
• W2801785887 hasConceptScore W2801785887C118487528 @default.
• W2801785887 hasConceptScore W2801785887C126322002 @default.
• W2801785887 hasConceptScore W2801785887C142724271 @default.
• W2801785887 hasConceptScore W2801785887C167734588 @default.
• W2801785887 hasConceptScore W2801785887C169760540 @default.
• W2801785887 hasConceptScore W2801785887C185592680 @default.
• W2801785887 hasConceptScore W2801785887C2776403814 @default.
• W2801785887 hasConceptScore W2801785887C2776694085 @default.
• W2801785887 hasConceptScore W2801785887C2776694393 @default.
• W2801785887 hasConceptScore W2801785887C2777025900 @default.
• W2801785887 hasConceptScore W2801785887C2777093970 @default.
• W2801785887 hasConceptScore W2801785887C2777802072 @default.
• W2801785887 hasConceptScore W2801785887C2778024200 @default.
• W2801785887 hasConceptScore W2801785887C2778561011 @default.
• W2801785887 hasConceptScore W2801785887C2779742858 @default.
• W2801785887 hasConceptScore W2801785887C2780827179 @default.

• next